DelveInsight’s “Polycythemia Vera Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Polycythemia Vera market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Polycythemia Vera drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Polycythemia Vera treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Polycythemia Vera: An Overview
Polycythemia Vera (PV) is characterized by an increased number of red blood cells in the bloodstream (erythrocytosis); affected people may also have excess white blood cells and platelets. Most cases of PV are not inherited and are acquired during a person’s lifetime. Mutation in the JAK2 kinase is responsible for PV. Most PV cases are associated with somatic genetic changes, which pass on genetic information to offspring. PV is usually diagnosed at the average age of people 60–65 years. It is uncommon in people under the age of 40. PV develops more often in men than in women.
In the early stages, there are not any specific signs and symptoms. When too many RBCs and platelets build up in the blood, symptoms start to appear, which may cause a problem. The symptoms are not noticeable due to an increased cell count but can predict a higher risk of clot formation.
Headache, dizziness, fatigue, blurred vision or blind spots, shortness of breath, itchy skin, spleen enlargement (Splenomegaly), blood clots, heavy bleeding, and others are the symptoms of PV. The most precarious symptom of polycythemia vera is the chance for a thrombotic event that can cause a heart attack or stroke. There is also a small chance that polycythemia vera could cause an individual to develop leukemia.
Polycythemia Vera Market Key Facts
The total market size of Polycythemia Vera in the 7MM is approximately USD 1,800 million in 2022.
Among EU4 countries, Germany accounts for the maximum market size in 2022 while Spain occupies the bottom of the ladder in 2022
The market size of Polycythemia Vera in Japan is USD 100 million in 2022.
The total market size of Polycythemia Vera in the United States is expected to increase with a CAGR of 14% during the study period (2019-2032).
The total prevalent cases of Polycythemia Vera in the 7MM comprised approximately 309,000 cases in 2022 and are projected to increase during the forecasted period
The total prevalent cases of Polycythemia Vera in the United States were around 179,000 cases in 2022
Among the EU4 countries, Germany accounted for the largest number of Polycythemia Vera cases followed by France, whereas Spain accounted for the lowest number of cases in 2022
In Japan, the prevalent Polycythemia Vera cases were around 13,000 in males and 7,000 in females in 2022.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Polycythemia Vera pipeline therapies. It also thoroughly assesses the Polycythemia Vera market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Polycythemia Vera drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Polycythemia Vera Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Polycythemia Vera epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Polycythemia Vera epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Polycythemia Vera Epidemiology, Segmented as –
Total Prevalent Cases of Polycythemia Vera in the 7MM [2019-2032]
Risk-specific Cases of Polycythemia Vera in the 7MM [2019-2032]
Gender-specific Cases of Polycythemia Vera in the 7MM [2019-2032
Age-specific Cases of Polycythemia Vera in the 7MM [2019-2032]
Based on Symptoms Cases of Polycythemia Vera in the 7MM [2019-2032]
Mutation-specific Cases of Polycythemia Vera in the 7MM [2019-2032]
Polycythemia Vera Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Polycythemia Vera market or expected to be launched during the study period. The analysis covers the Polycythemia Vera market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Polycythemia Vera drugs based on their sale and market share.
The report also covers the Polycythemia Vera pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Polycythemia Vera companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Polycythemia Vera Market Will Evolve and Grow by 2032 @
Polycythemia Vera Therapeutics Analysis
The treatment for PV is based on the symptoms and progression, as well as the age of the patients. The goal of treatments for PV is to control symptoms and lower the risk of complications. Treatments like phlebotomy help make the blood thinner when there are too many red blood cells. It is done the same way as donating blood, and drugs like hydroxyurea, interferon alfa, etc., are used. Various other supportive therapies, antihistamines, allopurinol, and aspirin, are also recommended. To date, JAKAFI/JAKAVI and BESREMi are the only two drugs approved for treating Polycythemia Vera by the US FDA.
To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Polycythemia Vera. Currently, Protagonist Therapeutics is leading the therapeutics market with its Polycythemia Vera drug candidates in the most advanced stage of clinical development.
Polycythemia Vera Companies Actively Working in the Therapeutics Market Include
AOP Orphan Pharmaceuticals AG
Kartos Therapeutics, Inc.
And Many Others
Emerging and Marketed Polycythemia Vera Therapies Covered in the Report Include:
BESREMi (ropeginterferon alfa-2b): PharmaEssentia/AOP Orphan Pharmaceuticals
Bomedemstat (IMG-7289): Imago BioSciences
Jakafi (Ruxolitinib): Incyte Corporation/Novartis
JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis
KRT-232: Kartos Therapeutics
PPMX-T003: Perseus Proteomics
PTG-300: Protagonist Therapeutics
Rusfertide (PTG-300): Protagonist Therapeutics
Sapablursen (IONIS-TMPRSS6-LRx): Ionis Pharmaceutical
SLN124: Silence Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Polycythemia Vera Competitive Intelligence Analysis
4. Polycythemia Vera Market Overview at a Glance
5. Polycythemia Vera Disease Background and Overview
6. Polycythemia Vera Patient Journey
7. Polycythemia Vera Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Polycythemia Vera Treatment Algorithm, Current Treatment, and Medical Practices
9. Polycythemia Vera Unmet Needs
10. Key Endpoints of Polycythemia Vera Treatment
11. Polycythemia Vera Marketed Therapies
12. Polycythemia Vera Emerging Drugs and Latest Therapeutic Advances
13. Polycythemia Vera Seven Major Market Analysis
14. Attribute Analysis
15. Polycythemia Vera Market Outlook (In US, EU5, and Japan)
16. Polycythemia Vera Companies Active in the Market
17. Polycythemia Vera Access and Reimbursement Overview
18. KOL Views on the Polycythemia Vera Market
19. Polycythemia Vera Market Drivers
20. Polycythemia Vera Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Dystrophy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Corneal Dystrophy market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States